SENores PHARMA | FY25 ANNUAL REPORT — WHAT INVESTORS SHOULD KNOW 🔍
Senores Pharmaceuticals delivered a breakout year in its first year as a listed company.
📈 Revenue +92% YoY
🔥 EBITDA +148% YoY
📊 EBITDA Margin: 27% | +640 bps
🇺🇸 ~70% revenue from the US
The strategy is clear: focus on specialty, niche & complex generics where competition is relatively lower.
🚀 Growth Engines
• CDMO/CMO: 22 commercial products + 69 in pipeline
• API backward integration: Gujarat capacity expanded 25 → 169 MTPA
• Injectables: ₹43.55 Cr IPO allocation
• Acquisitions of Havix & Ratnatris strengthening the global platform
• Emerging markets targeted for higher-value niche molecules
💰 Financial & Governance Check
Consolidated contingent liabilities: ₹20.93 Cr, largely disputed income-tax demands.
Management remuneration stood at ₹8.49 Cr, while MD remuneration rose 236.7% YoY vs 78.3% PAT growth — worth monitoring.
Auditor gave a clean/unmodified opinion, with revenue recognition identified as a key audit area.
⚠️ KEY RISK
The biggest opportunity is also a major risk:
~70% revenue comes from the US.
That provides scale and access to an attractive market, but increases exposure to US regulatory changes, pricing pressure and protectionist policies.
🧠 NEHA GUPTA | SEBI RA
Senores is transitioning from a high-growth pharma manufacturer → vertically integrated platform through APIs, injectables, CDMO and complex generics.
The numbers show strong execution.
Now the real test is:
Can capacity expansion + pipeline + acquisitions translate into sustainable cash flows and returns?
That’s the key metric I’ll be watching.
— Neha Gupta
SEBI Registered Research Analyst
For educational purposes only. Not investment advice.